Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an oral, direct-acting, reversible P2Y12 receptor antagonist used to prevent thrombotic events. It is part of a class of drugs known as antiplatelet agents.
## Primary Indications
* **Acute Coronary Syndrome (ACS):** To reduce the rate of thrombotic cardiovascular events (including stent thrombosis) in patients with a history of myocardial infarction (MI) or ACS.
* **Secondary Prevention in Patients with ACS:** Following PCI in patients with ACS.
## Adult Dosing
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months.
* In certain situations, after 12 months of treatment, the dose may be reduced to 60 mg orally twice daily.
* Maximum dose: 180 mg per day (loading dose), 90 mg twice daily (maintenance).
## Pediatric Dosing
There is no established pediatric dosing for ticagrelor.
## Dose Adjustments
* **Hepatic Impairment:** No dose adjustment is required in patients with mild to moderate hepatic impairment. Safety and efficacy have not been studied in severe hepatic impairment.
* **Renal Impairment:** No dose adjustment is required in patients with mild to moderate renal impairment. Caution is advised in severe renal impairment due to limited data.
## Contraindications
* Hypersensitivity to ticagrelor or any component of the formulation.
* Active pathological bleeding.
* History of transient ischemic attack (TIA) or stroke.
## Adverse Effects
* **Common:** Dyspnea, bleeding (major and minor, including gastrointestinal, intracranial, and subcutaneous), bradyarrhythmia.
* **Serious:** Severe bleeding, anaphylaxis, ventricular pauses, Churchill-Danforth syndrome.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase ticagrelor exposure. Potent CYP3A4 inducers (e.g., rifampin, carbamazepine) can decrease ticagrelor exposure.
* **Strong CYP3A4 Substrates:** Ticagrelor inhibits CYP3A4, increasing the exposure of concomitant strong CYP3A4 substrates (e.g., simvastatin, atorvastatin).
* **Aspirin:** Co-administration with aspirin (beyond the initial loading dose in ACS) increases the risk of bleeding.
* **Other Antithrombotics:** Concomitant use with other anticoagulants or antiplatelets increases the risk of bleeding.
* **Omeprazole:** Concurrent use with omeprazole may reduce ticagrelor exposure.
## Monitoring
* **Bleeding:** Closely monitor for signs and symptoms of bleeding.
* **Cardiac Rhythm:** Monitor for bradycardia, particularly in patients with risk factors.
* **Platelet Aggregation:** Not routinely recommended, but may be considered in specific clinical scenarios.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, which may offer an advantage over irreversible inhibitors in situations requiring a rapid offset of antiplatelet effect.
* Dyspnea is a common side effect and is generally not associated with cardiac or pulmonary disease. It often resolves with continued therapy.
* Due to its reversible binding, discontinuation of ticagrelor may lead to a faster return of platelet function compared to clopidogrel.
* The choice of ticagrelor dose (90 mg vs. 60 mg twice daily) after the initial 12 months of therapy in ACS patients should be individualized based on risk of ischemic events versus bleeding risk.
***
*Please verify current prescribing information for complete details before administration.*
